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Commentary: Reoperative
transapical transcatheter aortic
valve implantation for a
degenerated biological valve: An
approach with caution or a
mission impossible?
Thomas Theologou, MD, FRCSC-Th,a and
Tom C. Nguyen, MDb
We read with great interest the case report by Ricciardi and
colleagues1 describing reoperative transapical (TA) trans-
catheter aortic valve implantation (TAVI) for a degenerated
biological valve in a high-risk patient. The authors describe
a 73-year-old patient with severe peripheral vascular
disease and inadequate iliofemoral vessels. The patient
initially underwent a TA TAVR using a 23-mm Edwards
SAPIENXT prosthesis but presented approximately 7 years
later with structural valve deterioration. The authors subse-
quently proceeded with a redo TATAVR and concluded that
this is a viable approach in frail patients with failed trans-
catheter valves, although further studies are needed.
We should congratulate the authors for the success of
their case, but we would like to emphasize that redo TA
TAVR should be approached with caution. The authors
did provide practical and thoughtful pearls and pitfalls,
including a step-by-step structured methodology to safely
identify the left ventricular apex using transthoracic echo-
cardiography, and the suggestion to directly enter the car-
diac apex from the previous scar, leaving pericardium and
previous Teflon pledgets intact. By leaving adhesions and
previous Teflon pledgets on the apex, this provides a support
structure to facilitate closing the puncture site at the end of
the procedure. Looking at the literature, other authors, on
the contrary, were removing the Teflon pledgets.2
Several points are noteworthy when considering redo TA
TAVR, including: (1) the patient’s access complexity, (2)
the balance between risks and benefits of performing this
procedure, and careful informed consent of the patient
and his/her family (3) the previous experience of the sur-
geon and her/his team in similar cases, and (4) the choice
of a correct size of the transcatheter valve to prevent prema-
ture valve degeneration.
Finally, further investigating this redo TA TAVR with a
randomized control trial or an observational study may pre-
sent ethical and practical issues. These cases are relatively
rare and may be difficult to recruit patients for the study.
The risk of aortic or left ventricular rupture is tangible
and may not justify randomization. This provides a one-
way ticket with no return journey, as even if an emergency
surgery could be performed after a complicated redo TA
TAVI, it will inevitably portend an adverse outcome.
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catheter aortic valve implanta-
tion for a degenerated biological
valve is feasible but should be
proceeded with caution, as out-
comes could be disastrous.
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